Hollis RL, et al. - In isolated lymph node relapse ovarian carcinoma vs extranodal relapse ovarian carcinoma, researchers compared the clinical outcome, tumor-infiltrating lymphocyte burden, and frequency of known prognostic genomic events. Forty-nine isolated lymph node relapse patients with ovarian carcinoma have been identified and matched to 49 cases of extranodal relapse using the Edinburgh Ovarian Cancer Database from which the clinical data for identified patients have been collected. Compared to extranodal relapse, isolated lymph node relapse ovarian carcinoma represents a distinct clinical entity with favorable outcome. In the isolated lymph node relapse ovarian carcinoma cohort, there was no clear enrichment or depletion of BRCA1/2 mutation or CCNE1 gain relative to extranodal relapse cases, indicating that these known prognostic genomically defined disease subtypes do not show a significantly modified propensity to isolated lymph node relapse. Diagnostic tumor material from patients with isolated lymph node relapse showed greater CD3+ and CD8+ cell infiltration, suggesting stronger tumor engagement by T cell populations, which may add to the more indolent disease course of isolated lymph node relapse.